Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. on June 4, 2021. The filing discloses updated interim clinical results from the Phase 1/2a study of PBCAR0191, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 for relapsed or refractory non-Hodgkin lymphoma (R/R NHL). Additionally, the Company announced the selection of initial clinical trial sites and the opening of enrollment for the Phase 1 study of PBCAR19B, a next-generation stealth cell candidate.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and regulatory disclosures.
Material Changes and Clinical Results
As of May 21, 2021, 18 subjects with R/R NHL completed Day 28 evaluation in the PBCAR0191 study. Key findings include:
- Lymphodepletion Impact: Enhanced lymphodepletion (eLD) markedly increased peak cell expansion (~72x) and area under the curve (~59x) compared to standard lymphodepletion (sLD), mitigating rejection.
- Efficacy (eLD Group, n=12):
- Overall Response Rate (ORR): 75%
- Complete Response (CR) Rate: 50%
- Five of nine responding patients (56%) remained progression-free, with four showing responses lasting greater than 4 months.
- Safety: No evidence of graft versus host disease (GvHD) was observed. Infections occurred more frequently in the eLD group (25% Grade 3+). Three treatment-emergent deaths occurred without disease progression (two due to infection, one cardiac arrest); only one was assessed as possibly related to study treatment.
- Patient Demographics: Over 80% of subjects had advanced/aggressive lymphomas, 75% had Stage III/IV disease, and the median number of prior therapy lines was seven.
Outlook, Guidance, and Risks
The Company announced that enrollment is open for the Phase 1 study of PBCAR19B. The study will evaluate increasing flat dose levels starting at 2.7 x 10^8 cells. Management indicated a conference call was held to review data. The filing includes standard forward-looking statement disclaimers regarding clinical development risks, referencing the "Risk Factors" section of the Company's Form 10-Q for the period ended March 31, 2021.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis of the PBCAR0191 trial.
- Review the Company's Form 10-Q for the quarter ended March 31, 2021, for financial liquidity and risk factor details.
- Monitor the duration of response data for the 56% of patients who remained progression-free.
- Track enrollment progress and initial safety data for the new PBCAR19B Phase 1 study.
- Confirm the specific causes of the three treatment-emergent deaths to assess safety profile implications.